Regeneron Secures EU Libtayo Dosing Flexibility and FDA Approval for First siRNA Myasthenia Therapy

SentiSense · Published · Updated

Regeneron Pharmaceuticals received European Commission clearance for a more flexible six‑week dosing regimen of its cancer drug Libtayo, allowing a 700 mg dose after initial treatment. The company also won U.S. FDA approval for Livsayis, the first siRNA therapy targeting generalized myasthenia gravis. Both milestones broaden Regeneron's oncology and neurology portfolios and could boost its market position.

REGN won two regulatory decisions this week. On November 18 the FDA approved Livsayis (cemdisiran), the first siRNA therapy for generalized myasthenia gravis, for adults who are anti-AChR antibody-positive. A day earlier, the European Commission approved an extended Libtayo regimen of 700 mg every six weeks, after an initial 12 weeks at 350 mg every three weeks.

Livsayis is given as a subcutaneous injection four times a year. In the Phase 3 NIMBLE trial it improved patients' daily-living scores (MG-ADL) by 4.5 points at 24 weeks, against 2.2 points on placebo, and 76.6% of patients responded, against 44.1%. It carries a boxed warning for serious meningococcal infections and is available only through a restricted program. Regeneron licensed the drug from ALNY, which discovered it.

The Libtayo change applies across all six of the drug's approved EU cancer indications, and also allows shorter 15-minute infusions after a well-tolerated first dose. Fewer clinic visits can matter for a checkpoint inhibitor competing with larger rivals. A U.S. decision on the same regimen is expected in March 2027.

What to watch: Livsayis's launch pricing and uptake in a gMG market where several complement and FcRn drugs already compete, the European decision on Livsayis expected in the second half of 2027, and the March 2027 FDA decision on Libtayo dosing.

Related Stocks

Powered by SentiSense - Intelligent Market Analysis